TRACON Pharmaceuticals Inc (NASDAQ:TCON) shares traded 19.50% higher at $0.26 on Wall Street last session.
TCON stock price is now -1.10% away from the 50-day moving average and 10.58% away from the 200-day moving average. The market capitalization of the company currently stands at $11.93M.
With the price target maintained at $14, BTIG Research recently Upgraded its rating from Neutral to Buy for TRACON Pharmaceuticals Inc (NASDAQ: TCON). On February 10, 2021, Maxim Group recently initiated its ‘Buy’ rating on the stock quoting a target price of $24, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, THEUER CHARLES, President and CEO bought 47,000 shares of the company’s stock on Apr 27 ’23. The stock was bought for $35,250 at an average price of $0.75. Upon completion of the transaction, the President and CEO now directly owns 399,417 shares in the company, valued at $0.1 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 26 ’23, President and CEO THEUER CHARLES bought 3,999 shares of the business’s stock. A total of $2,639 was incurred on buying the stock at an average price of $0.66. This leaves the insider owning 352,417 shares of the company worth $91628.42. A total of 11.53% of the company’s stock is owned by insiders.
During the past 12 months, TRACON Pharmaceuticals Inc has had a low of $0.13 and a high of $2.14. The fifty day moving average price for TCON is $0.2653 and a two-hundred day moving average price translates $0.2373 for the stock.
The latest earnings results from TRACON Pharmaceuticals Inc (NASDAQ: TCON) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $0.01, beating analysts’ expectations of -$0.08 by 0.09. This compares to -$0.30 EPS in the same period last year.
